Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL522873

CC(C)[SiH](C(C)C)C(C)C.ClCCl.O=C(O)C(F)(F)F

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228509-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2024-07-11 US disclosed
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-23 US disclosed
US-11964990-B2 1,3,4,7-tetrahydro-2H-pyrrolo[3′,2′:5,6]pyrido[2,3-b][1,4]oxazepine bcl-2 inhibitors ABBVIE INC. (US) 2024-04-23 US disclosed
WO-2024069229-A2 BIOLOGICALLY ACTIVE COMPOUNDS SUTURA THERAPEUTICS LTD (GB) 2024-04-04 WO disclosed
US-20240058450-A1 BCL-XL Inhibitory Compounds Having Low Cell Permeability and Antibody Drug Conjugates Including the Same ABBVIE INC (US) 2024-02-22 US disclosed
US-11897864-B2 Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2024-02-13 US disclosed
US-20240043404-A1 APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES ABBVIE INC. (US) 2024-02-08 US disclosed
US-11891457-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-06 US disclosed
US-20230399340-A1 MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE ABBVIE INC (US) 2023-12-14 US disclosed
US-11786519-B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases ABBVIE INC. (US) 2023-10-17 US disclosed
US-20060189636-A1 Inhibitors of E1 activating enzymes MILLENNIUM PHARMACEUTICALS, INC. (US) 2006-08-24 US disclosed
US-20050037974-A1 Affinity markers for human serum albumin CONJUCHEM, INC. (CA) 2005-02-17 US disclosed
EP-1485354-A1 SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE JANSSEN PHARMACEUTICA N.V. (BE) 2004-12-15 EP disclosed
WO-2003076401-A1 SULFONYLAMINO-DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE JANSSEN PHARMACEUTICA N.V. (BE) 2003-09-18 WO disclosed
US-20030032035-A1 Microfluidic device for analyzing nucleic acids and/or proteins, methods of preparation and uses thereof COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2003-02-13 US disclosed
WO-2002089972-A1 MICROFLUIDIC DEVICE FOR ANALYZING NUCLEIC ACIDS AND/OR PROTEINS, METHODS OF PREPARATION AND USES THEREOF COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 2002-11-14 WO disclosed
EP-1056474-B1 AFFINITY MARKERS FOR HUMAN SERUM ALBUMIN CONJUCHEM INC (CA) 2002-06-12 EP disclosed
EP-1199566-A1 Methods of screening affinity marker libraries Conjuchem, Inc. (CA) 2002-04-24 EP disclosed
EP-1056474-A2 AFFINITY MARKERS FOR HUMAN SERUM ALBUMIN ConjuChem, Inc. (CA) 2000-12-06 EP disclosed
WO-1999024075-A2 AFFINITY MARKERS FOR HUMAN SERUM ALBUMIN CONJUCHEM, INC. (CA) 1999-05-20 WO disclosed